Novartis

The pharmaceutical firm is buying The Medicines Company, which recently devoted its efforts into developing the cholesterol-lowering medication.

The agency is now evaluating the implications of the corrupted data behind Zolgensma and whether to “take action” against the pharmaceutical company.

At $2 million for a single dose, Novartis’s Zolgensma is the most expensive medicine to date, but still less expensive over a lifetime than another approved drug for the rare genetic disease.

A Novartis subsidiary is partnering with a Canadian cannabis company to sell medical marijuana worldwide.

If the UK leaves the EU in March without a deal, transport of insulin and other essential drugs could be delayed.

Aimovig will soon be available for individuals who have four or more migraines a month.

The drug company had an agreement with Essential Consultants, run by the president’s former attorney Michael Cohen.

The company has shuttered its experimental cell and gene cancer therapy unit, firing more than 100 researchers.

The technologically advanced eyewear monitors blood sugar concentrations in diabetic patients.

The pharmaceutical companies announce a suite of asset swaps that drove up share prices and will reshape both.